Navigation Links
Matt Bars, a Global Expert in Smoking Cessation, Joins Next Safety as Chairman
Date:4/27/2009

Next Safety, Inc. has developed the most effective pulmonary nicotine delivery device to help people quit smoking

JEFFERSON, N.C., April 27 /PRNewswire/ -- Matthew P. Bars, MS, CTTS, has joined Next Safety, Inc. (NSI) as chairman. In his smoking cessation work, he has appeared on the NBC Today Show several times, as well as the CBS Evening News with Dan Rather, ABC World News Tonight, CNBC and CNN.

Mr. Bars has a B.S. in Psychology, an M.S. in Clinical Psychology and is a member of the American Academy of Addiction Psychiatry. He is a consultant and key opinion-maker for many pharmaceutical, healthcare, and medical diagnostic companies and has been engaged in the treatment, management, and administration of nicotine addiction services since 1980.

Mr. Bars is a contributing editor to the National Cancer Institute's "Clearing the Air" stop-smoking publication. He is also the expert consultant and director for smoking cessation for the Fire Department of New York City and the co-developer of the "Tobacco Free with the New York FD" program. He is the current clinical director of the Palisades Medical Center's IQuit Smoking Program (an affiliate of the Columbia University New York Presbyterian Healthcare System and a director of the IQuit Smoking Consultation Service).

"I have worked against nicotine addiction for almost 30 years and I am excited to be working with a company that is poised to save lives with what I have named 'the Next Step' in nicotine replacement therapy," said Mr. Bars.

In human trials, utilizing the Next Safety Platform, the device was highly effective in the pulmonary delivery of nicotine and other drugs. The phase I trials included blood results that were independently measured by a leading laboratory at a major academic research institution. Participants reported significant psychoactive effects.

NSI's proprietary platform is a powerful new method for the pulmonary delivery of drugs; the small handheld device will allow the user to inhale nicotine vapor and other drugs from an air stream with a high degree of control and safety. The company's manufacturing partners for the production of its nicotine delivery device are large global companies with more than 150 combined international sites, including a number of FDA-approved manufacturing facilities in the US.

NSI has an agreement with a major US-based pharmaceutical company to supply pharmaceutical-grade nicotine. NSI expects the price of an equivalent amount of nicotine delivered by its device, as compared to the amount of nicotine delivered by a carton of cigarettes, to be less than 10% of the current average market price in the US.

In addition, NSI is testing other drugs that use its new pulmonary drug delivery platform for a number of leading pharmaceutical companies. These drugs include treatments for asthma, pulmonary infections, and the delivery of proteins to treat certain types of cancer as well as insulin and proteins for treating other conditions.

    Contact:

    Eric Hunter
    336-246-7700

http://www.nextsafety.com

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Next Safety, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Akaza Research to Present OpenClinica at ACRP Global Conference & Exhibition
2. Bayer CropScience Donates $1.1 Million to United Fresh Research & Education Foundation to Create the Center for Global Produce Sustainability
3. Setting the Benchmark for Winery Tasting Room Research: An Emerging Region Gets a Global Perspective
4. TechConnect Summit Brings the Global Technology Community to Houston, May 4-6, 2009
5. DuPont Leader: Agriculture is Up to Global Productivity Challenge
6. ACM Global Central Lab Announces Partnership with Chindexs United Family Hospitals in China
7. Global Aviation Summit Explores Low-Carbon Flight
8. Global Med Technologies(R) Licenses 90th Site in the Southeastern U.S.
9. NovaBay and Galderma Enter Into Global Agreement to Develop and Commercialize NovaBays Novel Aganocide Drugs for Major Dermatological Conditions
10. Forward-Thinking Patient Recruitment Company Poised to Create Bridges Between Japanese Clinical R&D Industry and Global Clinical Trial Marketplace
11. 3rd Global Jatrophaworld Training 2009... Set to Create and Build a Sustainable non-food Biodiesel Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... Md. , March 27, 2017  The ... billion for 2016, according to a new report ... medical lab testing is performed to evaluate disease ... individual therapy, among other reasons.  The healthcare market ... Market , provides an overview of the ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... ... method to engineer scalable and customizable vascular grafts in JoVE’s Video Journal, the ... lead to new and improved ways of treating coronary artery disease (CAD). Lam ...
(Date:3/24/2017)... March 24, 2017 MiMedx Group, Inc. (NASDAQ: ... human placental tissue allografts and patent-protected processes to develop ... of healthcare, announced today  that it will present at ... , NY.  Parker H. "Pete" Petit, Chairman and ... Christopher M. Cashman , EVP and Chief Commercialization ...
(Date:3/24/2017)... 2017 On Thursday, March 23, ... 5,817.69, down 0.07%; the Dow Jones Industrial Average edged ... 500 closed at 2,345.96, marginally dropping 0.11%. US markets ... green, 4 sectors finished in red, and 1 sector ... initiated reports coverage on the following Biotechnology equities: BioDelivery ...
Breaking Biology Technology:
(Date:3/23/2017)... 23, 2017 Research and Markets has announced ... & Trends - Industry Forecast to 2025" report to their ... The ... CAGR of around 8.8% over the next decade to reach approximately ... the market estimates and forecasts for all the given segments on ...
(Date:3/22/2017)... 2017 Optimove , provider of ... such as 1-800-Flowers and AdoreMe, today announced two ... Replenishment. Using Optimove,s machine learning algorithms, these features ... replenishment recommendations to their customers based not just ... customer intent drawn from a complex web of ...
(Date:3/20/2017)... At this year,s CeBIT Chancellor Dr. Angela Merkel ... came to the DERMALOG stand together with the Japanese Prime Minster Shinzo ... At the largest German biometrics company the two government leaders could see ... as well as DERMALOG´s multi-biometrics system.   Continue ... ...
Breaking Biology News(10 mins):